Berlin, Germany, March 30, 2016 - Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces that it has entered a strategic license agreement with BioChain on the development and commercialization of a novel, blood-based lung cancer test for China.
BioChain will initiate a clinical trial to validate the lung cancer detection test with the goal to gain market approval by the CFDA. The trial is expected to start in 2016. The product development will be based on Epigenomics’ novel panel of blood-based DNA methylation biomarkers that has shown promising results in a clinical validation study.
Under the terms of the agreement, Epigenomics will receive undisclosed upfront, milestone and minimum annual payments as well as mid single-digit royalty on future revenues. Lung cancer diagnosis remains challenging worldwide. In view of the high, rapidly growing prevalence of lung cancer among the Chinese population, the commercialization of a novel, blood-based test represents a major business opportunity for both companies. Epigenomics is entitled to commercialize this product in other markets outside China.
